The type 2 diabetes market is expanding rapidly, fueled by increasing prevalence and a wave of recent product launches. Sanofi’s Suliqua (lixisenatide/insulin glargine), Novo Nordisk’s Fiasp, and AstraZeneca’s Glyxambi (linagliptin/empagliflozin) are examples of recent European product approvals. DRG believes the positive results from the EMPA-REGCVOT for Boehringer Ingelheim’s/Eli Lilly’s Jardiance will benefit uptake of the entire SGLT-2 inhibitor class. Current Treatment explores how the prescribing behaviors of European endocrinologists have changed in response to the rise of the SGLT-2 inhibitors and how other novel drugs compare.

Table of contents

  • Detailed, Expanded Analysis: Physician Insights (EU5)
    • Introduction to Current Treatment for Type 2 Diabetes
      • SGLT-2 Inhibitors and GLP-1 Receptor Agonists Benefit from CV and Weight Loss Effects
      • Introduction to Current Treatment and Medical Practice for Type 2 Diabetes
    • Physician Prescribing Practices
      • Patient Share of GLP-1 Receptor Agonists and SGLT-2 Inhibitors Set to Grow
      • Patient Characteristics
        • Mean Lab Values, BMI, and Prevalence of Complications Reflect Type 2 Diabetes Disease Severity
      • Treatment Practices
        • SGLT-2 Inhibitors and GLP-1 Receptor Agonists Prominent in Treatment Algorithm
        • Time to Treatment Start
        • Treatment Rates
        • Patient Share by Product
        • Treatment Duration by Product
        • Line of Therapy Analysis
        • Combination/Regimen/Comedication Analysis
      • Persistency and Compliance
        • The Most Popular Antidiabetic Classes Have Compliance Rates of 60-70%
      • Sequencing of Treatment
        • SGLT-2 Inhibitors Are Incorporated into Early Lines of the Treatment Algorithm
      • Recent/Anticipated Changes in Brand Use/Treatment Approach
        • SGLT-2 Inhibitors and GLP-1 Receptor Agonists Anticipated to Have Greatest Increase in Use
    • Physician Insight on Medical Practice
      • CV End Points and Weight Loss Are Key Differentiators in Type 2 Diabetes
      • Drivers of Treatment Selection
        • Balance of Efficacy and Hypoglycemia Drives Treatment
        • Factors Influencing Treatment and Disease Management
        • Major Drivers of Brand Use/Treatment
        • Major Obstacles to Brand Use/Treatment
        • Treatment Failure/Brand Issues
    • Methodology
      • Primary Market Research Methodology
    • Appendix
      • Primary Market Research

Author(s): Gideon Heap

As a Principal Analyst on the Cardiovascular, Metabolic and Renal Disorders team, Gideon has a wealth of experience and expertise in pharmaceutical market analysis. In addition to creating Disease Insights covering metabolic disorders, Gideon has experience in company strategy and portfolio analysis for DRG’s Company & Drug platform. Gideon has a Masters in Biochemistry with Biological Chemistry from the University of Nottingham, and his industry experience dates back to 2009.


Related Reports

Type 2 Diabetes | Unmet Need | Detailed, Expanded Analysis: Injectables (US/EU)

The type 2 diabetes (T2D) therapy market is expected to expand, fueled by a rich pipeline of agents. However, growth will be tempered because these emerging therapies will be predominantly later-...

View Details

Type 2 Diabetes | Geographic Focus: China | Type 2 Diabetes | China In-Depth | China

Type 2 diabetes (T2D) is one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Traditional therapies such as...

View Details

Type 2 Diabetes | Landscape & Forecast | Disease Landscape & Forecast

The type 2 diabetes therapy market will steadily expand over the 2017-2027 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the diseas...

View Details

Type 2 Diabetes | Access & Reimbursement | Detailed, Expanded Analysis (EU) Top 5 European Markets

MARKET OUTLOOK Type 2 diabetes (T2D) has an extremely high prevalence in the top five European markets (France, Germany, Italy, Spain, UK). Low-cost metformin (Merck Kg...

View Details